Published October 12, 2015 | Version v1
Journal article

Establishment of monoclonal HCC cell lines with organ site-specific tropisms

  • 1. Department of Oncology, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong Province 256603 People's Republic of (China)
  • 2. Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032 (China)
  • 3. Cancer Research Institute, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Central South University, Changsha, Hunan (China)
  • 4. Institute of Biomedical Sciences of Fudan University, Shanghai, 200032 (China)
  • 5. Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032 (China)

Description

Organ site-specific metastasis is an ominous feature for most poor-prognostic hepatocellular carcinoma (HCC) patients. Cancer cell lines and animal models are indispensable for investigating the molecular mechanisms of organ specific tropism. However, till now, little is known about the drivers in HCC metastatic tropism, and also no effective way has been developed to block the process of tropistic metastasis. In this study, we established several monoclonal HCC cell lines from HCCLM3-RFP together with their xenograft models, and then analyzed their metastatic potentials and tropisms using in-vitro and in-vivo assays, and finally elucidated the driving forces of HCC tropistic metastases. Six monoclonal cell lines with different organ site-specific tropism were established successfully. SPARC, VCAM1 and ANGPTL4 were found positively correlated with the potentials of lung metastasis, while ITGA1 had a positive relation to lymph node metastasis of enterocoelia. By our powerful platforms, HCC metastatic tropisms in clinic could be easily mimicked and recapitulated for exploring the bilateral interactions between tumor and its microenvironment, elucidating the drivers of HCC metastatic tropisms, and testing anti-cancer effects of newly developed agent in pre-clinical stage. The online version of this article (doi:10.1186/s12885-015-1692-0) contains supplementary material, which is available to authorized users

Availability note (English)

Available from http://dx.doi.org/10.1186/s12885-015-1692-0; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603809

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
15
Journal Page Range
vp.
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47084253
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
HEPATOMAS; IN VITRO; IN VIVO; LYMPH NODES; METASTASES
Descriptors DEC
CARCINOMAS; DISEASES; LYMPHATIC SYSTEM; NEOPLASMS

Optional Information

Copyright
Copyright (c) Wan et al. 2015
Notes
PMCID: PMC4603809; PMID: 26459277; PUBLISHER-ID: 1692; OAI: oai:pubmedcentral.nih.gov:4603809